Rainer Storb, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, elaborates on the most suitable method of myeloablative conditioning prior to allogeneic hematopoietic cell transplant (ASCT) for patients with myeloid malignancies. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.